Biotech news
Regulation & Industry
With billions in revenue set to disappear as patents expire, pharmaceutical giants are racing to acquire their way out of trouble. But are there other drivers behind the surge—and how long can the momentum last? 27 July 2026
Careers
The firm has added partners with expertise in life sciences, technology disputes and trademark strategy, alongside leadership changes at its Hong Kong affiliate. 27 July 2026
Pharma
Canada has firmly slammed the door on patenting methods of medical treatment—but the battle over what counts as a "medical method" is only just beginning. Scott MacKendrick of ROBIC examines a landmark decision that leaves the door ajar for future litigation over complex drug-dosing regimens. 23 July 2026
Biotech
Now a Danaher subsidiary, the company is contesting a number of orders after a California court finalised several aspects of the high-profile dispute. 21 July 2026
Biotech
The biotech company has launched a trio of lawsuits against two vaccine makers, while announcing receipt of a $178 million sum from Moderna under a previous deal. 20 July 2026
Regulation & Industry
Blockbuster acquisitions are back, impacting the pharma industry at record pace. As billions flow into breakthrough science, LSIPR’s series explores what’s driving the surge, how today’s deals are done, and where IP comes into the picture. 17 July 2026
Biotech
A Munich court ruled that Illumina infringed a rival’s DNA sequencing patents, handing the challenger an early victory in a dispute that is playing out across Europe and the US. 16 July 2026
Careers
A high-profile hire will co-chair the firm's new office, bringing experience across biotech, therapeutics, genomics, diagnostics, and medical devices. 16 July 2026
Biotech
French drugmaker's Translate Bio unit accuses COVID rivals of infringing core lipid nanoparticle and mRNA purification patents, seeking damages from vaccines worth billions. 15 July 2026
In-house counsel
The company’s VP of IP explains how he is protecting the process, staying ahead of outside counsel, and why a biosimilar path is only a matter of time. 13 July 2026